Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ERAS | US
-0.98
-4.36%
Healthcare
Biotechnology
30/06/2024
24/04/2026
21.49
22.49
22.84
20.73
Erasca Inc. a clinical-stage biopharmaceutical company focuses on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007 an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer colorectal cancer and acute myeloid leukemia; and ERAS-601 an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801 a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego California.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
92.6%1 month
82.8%3 months
71.6%6 months
100.6%-
-
1.75
0.12
0.10
-1.57
-
-
-143.95M
5.84B
5.84B
-
-
-
-
-38.90
12.22
13.56
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
10.28
Range1M
10.28
Range3M
15.23
Rel. volume
0.98
Price X volume
123.28M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Grifols S.A | GRFS | Biotechnology | 8.08 | 6.31B | 1.13% | 33.27 | 190.24% |
| Arcellx Inc. Common Stock | ACLX | Biotechnology | 115.03 | 6.18B | -0.02% | n/a | 15.25% |
| Praxis Precision Medicines Inc | PRAX | Biotechnology | 344.82 | 6.12B | 4.62% | n/a | 0.46% |
| Tilray Inc | TLRY | Drug Manufacturers-Specialty & Generic | 6.75 | 6.10B | -2.74% | n/a | 6.83% |
| Protagonist Therapeutics Inc | PTGX | Biotechnology | 100 | 5.89B | -2.55% | 17.27 | 2.03% |
| Amarin Corporation plc | AMRN | Biotechnology | 14.31 | 5.88B | -1.92% | n/a | 1.47% |
| Lyell Immunopharma Inc. Common Stock | LYEL | Biotechnology | 22.41 | 5.74B | -5.04% | n/a | 10.63% |
| TG Therapeutics Inc | TGTX | Biotechnology | 36.62 | 5.67B | -0.81% | 34.28 | 63.38% |
| Alkermes plc | ALKS | Biotechnology | 33.31 | 5.49B | -1.77% | 12.40 | 28.66% |
| Kymera Therapeutics Inc | KYMR | Biotechnology | 84.91 | 5.48B | -2.59% | n/a | 12.87% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| FBIN | FBIN | Building Products & Equipment | 41.54 | 5.16B | 0.34% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 79 | 4.18B | 0.24% | 23.44 | 27.88% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| LCI Industries | LCII | Recreational Vehicles | 120.01 | 3.06B | -0.45% | 25.82 | 77.66% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.11 | 3.04B | -1.15% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| HNI Corporation | HNI | Building Products & Equipment | 37.7 | 1.78B | 1.32% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.57 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.75 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 71.57 | 72.80 | Par |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 5.84B | 3.66B | Market Leader |